Abstract: The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having ?-folate receptor (FR?) binding domain and 4-1BB (CD137) costimulatory domain to treat ovarian cancer.

Abstract: There is provided a chimeric antigen receptor (CAR) comprising a CD19-binding domain which comprises a) a heavy chain variable region (VH) having complementarity determining regions (CDRs) with the following sequences: CDR1—GY-AFSSS (SEQ ID No. 1); CDR2—YPGDED (SEQ ID No. 2) CDR3—SLLYGDYLDY (SEQ ID No. 3); and b) a light chain variable region (VL) having CDRs with the following sequences: CDR1—SASSSVSYMH (SEQ ID No. 4); CDR2—DTSKLAS (SEQ ID No. 5) CDR3—QQWNINPLT (SEQ ID No. 6). There is also provided a cell comprising such a CAR, and the use of such a cell in the treatment of cancer, in particular a B cell malignancy.

Abstract: Nucleic acids that encode chemically-inducible fusion proteins, vectors that contain nucleic acids that encode chemically-inducible fusion proteins, chemically-inducible fusion proteins, chemically-inducible fusion protein complexes, and non-natural cells that are modified to express chemically-inducible fusion proteins to spatially and temporally control immune cell signal initiation and downstream responses for treating disease.

Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.

Abstract: The present invention relates to compositions and methods for the immunomodulation mediated by the interaction of PD-L2 and RGMb.

Abstract: The present disclosure relates to a novel antibody, in particular a monoclonal antibody, capable of binding to IGF-1R, as well as the amino and nucleic acid sequences coding for said antibody.

Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.

Abstract: The invention relates to antibody molecules and antigen-binding portions thereof which bind specifically to glucocorticoid-induced TNF receptor (GITR). In particular aspects of the invention, the antibody molecules specifically bind to human GITR and cynomolgus monkey GITR. The anti-GITR antibody molecules of the invention have been developed and optimized using CDR sequences derived from a murine anti-GITR antibody 6C8. Medical uses of the antibody molecules are disclosed.

Abstract: Methods and compositions involving polypeptides having an aglycosylated antibody Fc domain are provided. In certain embodiments, polypeptides have an aglycosylated Fc domain that contains one or more substitutions compared to a native Fc domain. Additionally, some embodiments involve an Fc domain that is binds some Fc receptors but not others. For example, polypeptides are provided with an aglycosylated Fc domain that selectively binds C1q, and optionally activating Fc receptors, but that is significantly reduced for binding to the inhibitory Fc?RIIb receptor. Furthermore, methods and compositions are provided for promoting complement dependent cytotoxicity (CDC) using a polypeptide having a modified aglycosylated Fc domain and a second non-Fc binding domain, which can be an antigen binding region of an antibody or a non-antigen binding region. Some embodiments concern antibodies with such polypeptides, which may have the same or a different non-Fc binding domain.

Abstract: Disclosed are methods and compositions for treating Type I diabetes in a subject. Agents selected from a TLR4 agonist, a TLR4/MD-2 agonist, or a combination thereof may be used in the disclosed methods and compositions. Also disclosed are methods of restoring adaptive immune T cell tolerance, treating pernicious insulitis, improving immune tolerance, and treating autoimmune diseases using the disclosed methods and compositions.

Abstract: Antibodies are provided which bind human and Macaca fascicularis CEACAM5 proteins, as well as isolated nucleic acids, vectors and host cells comprising a sequence encoding the antibodies. Also provided are immunoconjugates comprising the antibodies conjugated or linked to a growth-inhibitory agent, and to pharmaceutical compositions comprising the antibodies, or immunoconjugates of the invention. The antibodies or immunoconjugates are used for the treatment of cancer or for diagnostic purposes.

Abstract: The present invention provides methods for treating cancer using P2RX2 inhibitors, such as P2RX2 inhibitory antibodies, among others. The invention also features compositions containing P2RX2 inhibitors, methods of diagnosing patients with P2RX2-associated cancer, and methods of predicting the response of cancer in a subject to treatment with P2RX2 inhibitors.

Abstract: A framework fragment derived from a chicken antibody, in which an amino acid at a particular position is replaced by cysteine, a heavy chain variable region or a light chain variable region including the framework fragment, or an antibody including the heavy chain variable region or the light chain variable region does not induce or prevents formation of disulfide bonds between antibody molecules while maintaining activity and reactivity of the antibody. The antibody introduced with cysteine or an antigen-binding fragment thereof easily binds with a conjugation compound such as a chemotherapeutic drug, an enzyme, an aptamer, a toxin, an affinity ligand, or a detection label, thereby being applied to various fields for diagnosis or treatment of diseases.

Abstract: The provided scaffolds have heavy chains that are asymmetric in the various domains (e.g. CH2 and CH3) to accomplish selectivity between the various Fc receptors involved in modulating effector function, beyond those achievable with a natural homodimeric (symmetric) Fc molecule, and increased stability and purity of the resulting variant Fc heterodimers. These novel molecules comprise complexes of heterogeneous components designed to alter the natural way antibodies behave and that find use in therapeutics.

Abstract: The present invention relates to an antibody that specifically binds to an epitope in the N-terminal part (residues 1 to 79) of tissue factor pathway inhibitor (TFPI). An antibody according to the invention may be capable of neutralising TFPI inhibition of the TF/FVIIa complex, even in the presence of elevated levels of TFPI. Such antibodies may find utility in the treatment of subjects with a coagulopathy, such as those with haemophilia A or B, with or without inhibitors.

Abstract: The invention provides TIMP2 immunoassays with improved clinical performance, particularly when used in the evaluation of renal injuries. The immunoassays rely on the selection and use of antibodies and antibody pairs that exhibit improved assay performance when used in complex clinical specimens such as biological fluids, and particularly when used in rapid assay formats such as lateral flow test devices.

Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. In some embodiments, such anti-complement C1s antibodies inhibit proteolytic activity of C1s. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.

Abstract: The present invention relates to the interaction between JMJD6 protein and collagen and to the possibility of inhibiting this interaction for the prevention and treatment of fibrosis and of tumor metastases. The invention further relates to a compound that is able to block the interaction between collagen and JMJD6 protein, in particular the invention relates to a new monoclonal antibody that recognizes JMJD6 and is able to block this interaction.

Abstract: Provided is a method for obtaining high-yield, stable expression cell clones from myeloma cell lines in a protein-free culture medium. The method is used for industrial production of a recombinant antibody, and includes three stage: (1) adapting to a protein-free culture medium, statically culturing cells at a low density, and gradually reducing a fat-rich supplement to a chemical culture medium; (2) adapting to a protein-free culture medium; culturing cells at a high density, and using a perfusion fermentation system in a laboratory scale; and (3) screening high-yield, stable expression cell clones from the cells after fermentation ends. The cell clone may be used to produce a humanized anti-NeuGcGM3 14F7 recombinant antibody.

Abstract: The present disclosure relates to a multi-specific antibody molecule comprising or consisting of three polypeptides: a) a polypeptide chain of formula (I): (Vxx)nVx-Cx-X-V1; and b) a polypeptide chain of formula (II): (Vyy)nVy-Cy c) a polypeptide of formula (III): V2 wherein Vx represents a variable domain, Vxx represents a variable domain, Cx represents a constant region, X represents a linker, V represents a variable domain, Vy represents a variable domain, Vyy represents a variable domain, Cy represents a constant region, V2 represents a variable domain, n independently represents 0 or 1, wherein the polypeptide chain of formula (I) and the polypeptide chain of formula (II) is aligned such that the constant regions Cx and Cy are paired and the variable domains Vx and Vy are paired to form a binding domain and optionally a disulphide bond is present between V and V2, in particular where a disulphide bond is present.

Abstract: The invention relates to the purification of bispecific antibodies carrying a different specificity for each binding site of the immunoglobulin molecule from a mixture of monospecific antibodies. The bispecific antibodies are composed of a single heavy chain and two different light chains, one containing a Kappa constant domain and the other a Lambda constant domain. This invention in particular relates to the isolation of these bispecific antibodies from mixtures that contain monospecific antibodies having two Kappa light chains or portions thereof and monospecific antibodies having two Lambda light chains or portions thereof. The invention also provides the methods of efficiently purifying these bispecific antibodies.

Abstract: A process for manufacturing a solid thermoset foam includes the following successive stages: (a) providing an expandable and thermosetting composition including a first reactant chosen from reducing sugars and a second reactant chosen from primary amines, primary amine acid addition salts, secondary amines, secondary amine acid addition salts, and ammonium salts of formula Rn?(NH4+)n where n is an integer at least equal to 1 and Rn? represents the residue of an organic or inorganic acid; (b) introducing the expandable and thermosetting composition into a mold or applying the expandable composition to a support so as to form a film having a thickness at least equal to 1 mm; and (c) heating the expandable and thermosetting composition to a temperature at least equal to 140° C. to react the first reactant with the second reactant and to form, by polymerization and chemical foaming, a block of solid thermoset foam.

Abstract: Conjugated diene polymers such as a styrene-butadiene copolymer are sequentially brominated by reaction with a quaternary ammonium tribromide or quaternary phosphonium tribromide and halohydrated by reaction with an N-haloimide compound. This produces a brominated and halohydrated polymer with very good thermal stability. The product is useful as a flame retardant in a variety of polymer systems.

Abstract: According to an aspect of the invention, a curable rubber composition is provided which includes a high molecular weight diene elastomer; optionally, a carbon black composition; a silica composition; and a farnesene polymer comprising farnesene monomers. The farnesene polymer is modified with at least one silane group, has a number average molecular weight of 1,000 g/mol to 100,000 g/mol, and has a glass transition temperature of equal to or less than ?50° C. According to another aspect of the invention, a method for producing a rubber composition for use in a tire is provided. The method includes forming a composition by mixing a farnesene polymer modified with at least one silane group, a silica composition, a high molecular weight diene elastomer, and optionally a carbon black composition, the farnesene polymer comprising farnesene monomers; and curing the composition.

Abstract: An eductor, a process and apparatus for gas phase polymerization of olefins in a polymerization reactor are disclosed. The process and apparatus employ an eductor which has an inlet which makes a bend of less than about 90° toward the outlet after entering the mixing chamber of the eductor.

Abstract: The present invention relates to an aqueous resin dispersion, obtained by subjecting a polymerizable compound (C) containing a compound (C1) having a carbon-carbon unsaturated bond to an emulsion polymerization in the presence of a surfactant (A) and a surfactant (B) free from a radical-polymerizable substituent.

Abstract: High stereoregularity, highly active catalytic performance, and good hydrogen response can be obtained by homopolymerizing propylene in the presence of a catalyst that includes a solid catalyst component including titanium, magnesium, a halogen, a carbonate compound represented by the following formula, and a diether compound. Excellent polymerization behavior can also be obtained when effecting random copolymerization or block copolymerization. R1—O—C(?O)—O—Z—O—R2??(1) wherein R1 and R2 are a hydrocarbon group or a substituted hydrocarbon group having 1 to 24 carbon atoms, or a heteroatom-containing group, provided that R1 and R2 are either identical or different, and Z is a linking group that links two oxygen atoms through a carbon atom or a carbon chain.

Abstract: To provide a fluorinated compound capable of obtaining a cured product which is excellent in heat resistance and mold release and has a high Abbe number; a curable composition containing such a compound; and a cured product which is excellent in heat resistance and mold release and has a high Abbe number. The fluorinated compound is represented by the following formula (A): [Z—OCH2CF2CF2CF2OCFHCF2—X—]nQ??(A) where n is an integer of at least 1, Q is a n-valent organic group, X is —O—, —NH— or —S—, and Z is a group having at least one polymerizable functional group.

Abstract: A process to form an ethylene-based polymer comprising, in polymerized form, ethylene and at least one acid comonomer, said process comprising polymerizing a reaction mixture comprising the ethylene and the acid comonomer, in a reactor configuration comprising at least one Secondary compressor, at least one pressurization device, and at least one reactor selected from the following: at least one autoclave reactor, at least one tubular reactor, or a combination thereof; and wherein the reaction mixture is polymerized in the presence of at least one free-radical initiator, and at a pressure of at least 1000 Bar; and wherein at least a portion of a comonomer composition comprising at least a portion of the acid comonomer used in the polymerization, is compressed, to form a compressed comonomer composition, in the pressurization device, up to a discharge pressure ranging from 1000 Bar to 4000 Bar, and at a discharge temperature (DT) from 10 C to 100 C; and wherein the compressed comonomer composition bypasses the

Abstract: Supported Ziegler-Natta ethylene polymerization procatalyst comprising special bi-(oxygen containing ring) compounds as internal donor, as well as a process for preparing the same and use of such a procatalyst for preparing a catalyst system used in the polymerization of ethylene for producing high molecular weight polyethylenes.

Abstract: Star polymer occlusion complexes were prepared comprising i) an amphiphilic unimolecular star polymer having a crosslinked core covalently linked to 6 or more independent amphiphilic polymer arms, ii) a nutraceutical (such as coenzyme Q10), and iii) a cholesterol-lowering drug (such as simvastatin). An initial occlusion complex formed with the nutraceutical and the star polymer exhibited improved binding properties for the cholesterol-lowering drug, resulting in improved loading efficiencies for the cholesterol-lowering drug. The star polymer occlusion complexes have utility in the medical treatment of high blood cholesterol.

Abstract: A process for producing a liquid composition, which includes holding a fluorinated polymer having —SO2F groups at from 140 to 160° C. for at least 45 minutes, cooling it to less than 110° C. at a rate of at least 50° C./min, converting the —SO2F groups in the fluorinated polymer to ion exchange groups to obtain a fluorinated polymer having ion exchange groups, and mixing the fluorinated polymer having ion exchange groups and a liquid medium.

Abstract: A polymer comprising recurring units having an acid generator bound to the backbone, and recurring units having an optionally acid labile group-substituted carboxyl group and/or recurring units having an optionally acid labile group-substituted hydroxyl group is obtained by polymerizing corresponding monomers under such illumination that the quantity of light of wavelength up to 400 nm is up to 0.05 mW/cm2. The polymer avoids photo-decomposition of the acid generator during polymerization and concomitant deprotection reaction of the acid labile group when used in positive resist compositions. A pattern with high dissolution contrast and rectangularity is formed after development.

Abstract: The present invention relates to a diacrylate compound represented by general formula (1), a composition thereof, and a cured product of the compound/composition. In the formula, R denotes a hydrogen atom or a methyl group; R1, R2, R3, and R4 each independently denote a C1-6 linear or branched alkyl group, with the proviso that R1, R2, R3, and R4 are not all methyl groups. The present invention provides: a novel diacrylate compound which can provide a cured product having an excellent balance of physical properties such as low curing shrinkage, flexibility, resistance to bending, and low curling properties, and which can be used as a photo- or thermal-radical polymerizable monomer; a composition of the compound; and a cured product of the compound/composition.

Abstract: The present invention relates to an aqueous polymer emulsion comprising at least 30 wt. % of a vinyl copolymer (A), said vinyl copolymer comprising: (I) from 10 to 90 wt. % of 2-octyl acrylate monomer; (II) from 10 to 90 wt. % of at least one itaconate ester monomer according to formula (1) in which A and B may be different or the same and A and B are independently an alkyl group or an aryl group; and (III) from 0 to 80 wt. % of ethylenically unsaturated monomer other than (I) and (II); whereby the summed amount of (I), (II) and (III) is 100 wt. % and whereby the amount of vinyl copolymer (A) is given relative to the total weight amount of the polymers present in the emulsion.

Abstract: Provided is a modified hydrocarbon resin that provides a hot melt adhesive composition with low odor, excellent heat stability, and high adhesive properties. The modified hydrocarbon resin is obtained by hydrogenating a hydrocarbon resin comprising a plurality of specific monomeric unit in a specific range, and characterized in that: a degree of hydrogenation of the olefins, a degree of hydrogenation of the aromatic rings, a weight average molecular weight (Mw), a Z-average molecular weight (Mz), a ratio (Mz/Mw) of the Z-average molecular weight to the weight-average molecular weight, a Gardner color scale of a toluene solution of 50 mass %, and a difference between pre-hydrogenation and post-hydrogenation mixed aniline point (MMAP) are within the specific range.

Abstract: Metallic complexes having indenyl ligands can be used as an ingredient of a catalyst system. The catalyst system can be used in polymerizations of ethylenically unsaturated hydrocarbon monomers that include both olefins and polyenes. Embodiments of the catalyst system can provide interpolymers that include polyene mer and from 40 to 75 mole percent ethylene mer, with a plurality of the ethylene mer being randomly distributed. The catalyst system also can be used in solution polymerizations conducted in C5-C12 alkanes, yielding interpolymers that include at least 10 mole percent ethylene mer.

Abstract: The invention relates to a propylene homopolymer or copolymer having a comonomer in the copolymer selected from ethylene, C4-C20-alpha olefin, said propylene homopolymer or copolymer being free of phthalic compound. It further relates to a long-chain branched propylene homopolymer or copolymer (b-PP) having a comonomer in the copolymer selected from ethylene, C4-C20-alpha olefins, said long-chain branched propylene homopolymer or copolymer (b-PP) being free of phthalic compound. As well as their production processes and uses.

Abstract: A method of producing a polycarbodiimide polymer comprises heating a precursor compound at a desired temperature. The method further comprises combining the precursor compound, a diisocyanate compound, and a carbodiimidization catalyst to form a reaction mixture. Finally, the method comprises heating the reaction mixture for a first period of time at a first temperature, thereby reacting the precursor compound and the diisocyanate compound in the presence of the carbodiimidization catalyst to produce the polycarbodiimide polymer.

Abstract: The modified polycarbodiimide compound of the present invention is obtained by modifying a polycarbodiimide compound derived from a diisocyanate compound with at least one aliphatic amine selected from the group consisting of diethylamine, methylisopropylamine, tert-butylethylamine, di-sec-butylamine, dicyclohexylamine, 2-methylpiperidine and 2,6-dimethylpiperidine. The curing agent of the present invention comprises the modified polycarbodiimide compound of the present invention. The thermosetting resin composition of the present invention comprises a carboxyl group-containing resin having a carboxyl group in a molecule or an epoxy resin having two or more epoxy groups in one molecule, and the curing agent of the present invention.

Abstract: The present invention relates to the use of nitrogenous compounds of formula (I) and/or corresponding quaternized and/or protonated compounds for production of polyurethanes, to compositions comprising said compounds and also to polyurethane systems, in particular polyurethane foams, obtained using said compounds.

Abstract: A surfactant and a method of forming the surfactant having the formula (I) where a is an integer from 1 to 10, b is an integer from 0 to 10, R1 is —CH3 or —H, n is an integer from 0 to 20, and R2 is a moiety selected from the group consisting of (II), (III), (IV), (V), (VI), (VII) or (VIII) where m is an integer from 0 to 4. The surfactant can be used in a method for preparing a rigid polyurethane foam.

Abstract: The present invention relates to a linear or branched structured hydroxylated or carboxylated polyester resin that is free of unsaturated fatty acids, that is made from an acid component and an alcohol component, said acid component comprising at least one C4 to C6 carboxylic polyacid or anhydride, and at least one C5 to C54 carboxylic polyacid or anhydride, and with said alcohol component comprising at least one biobased polyol having a functionality of at least 2 bearing a 1,4:3,6-dianhydrohexitol unit, and at least one of two polyols b2) and b3).

Abstract: The present disclosure relates to polythioaminals with applications as carriers or delivery vehicles for therapeutic agents or other small molecule cargo. Polythioaminal block copolymer coupled to a therapeutic agent is a polymer-therapeutic conjugate that exhibits higher stability and longer life time in aqueous environments. The polythioaminal block copolymer coupled to a therapeutic agent can be synthesized by reacting hexahydrotriazines with a hydrophobic block precursor, a hydrophilic block precursor, a particle stabilizing segment precursor, and a cargo, such as a therapeutic agent, in a one pot synthesis. The ease of synthesizing the resulting polythioaminal block copolymer coupled to the therapeutic agent while offering the extended stability and polymer life time in aqueous environments make the polythioaminal block copolymer particularly attractive for therapeutic carriers.

Abstract: A method of preparing a polyalkylene carbonate resin is provided. More particularly, a method of preparing a polyalkylene carbonate resin capable of preventing polymer degradation and improving physical properties and quality of a final resin product, in which, after polymerization of polyalkylene carbonate, by-products are removed by using a large amount of water to purify a reaction mixture, and in a subsequence process of removing a catalyst residue, a primary purification method is conducted by using a filter so that a content of the catalyst in the reaction mixture is less than 1% by weight, is provided.

Abstract: An assembly or apparatus for use in relation to an assembly, wherein said assembly is subjected to a temperature of less than ?50° C. in use, wherein said assembly or apparatus includes a component which comprises a polymeric material (A) having a repeat unit of formula —O-Ph-O-Ph-CO-Ph- (I) wherein Ph represents a phenylene moiety; and wherein said polymeric material (A) has a melt viscosity of at least 0.50 kNsm?2.

Abstract: The invention relates to an efficient method for producing polyoxyalkylene polyols with equivalent molar masses between 9500 and 23000 g/mol from one or more H-functional starter compounds, and one or more alkylene oxides in the presence of a double metal cyanide catalyst, characterized in that the alkylene oxide metering rate is reduced once a calculated equivalent molar mass of between 8000 and 9500 g/mol is reached.

Abstract: The present invention relates to reaction products H of at least one cyclic urea U, at least one multifunctional aldehyde A and at least one polyol P, process for preparing thereof and compositions comprising thereof.

Abstract: The present invention provides carbamylation compositions of one or more urea compounds, one or more polyols and a monovalent transition metal or alkali metal catalyst (i), such as lithium ethylhexanoate, which compositions are substantially isocyanate free, enjoy reduced toxicity in comparison to tin catalysts, and which are useful in making polycarbamates which themselves provide compositions for making crosslinked polyurethanes.

Abstract: A method of manufacture of a polyetherimide composition includes contacting a substituted phthalic anhydride and an organic diamine in the presence of diphenyl sulfone, sulfolane, or a combination comprising at least one of the foregoing solvents at a temperature of greater than 130° C. to provide a bis(phthalimide) composition comprising diphenyl sulfone, sulfolane, or a combination comprising at least one of the foregoing solvents and a bis(phthalimide); and polymerizing the bis(phthalimide) and an alkali metal salt of a dihydroxy aromatic compound in the presence of diphenyl sulfone, sulfolane, or a combination comprising at least one of the foregoing to form a polyetherimide. The method does not require any catalyst either for the imidization or the polymerization.